Current Pharmaceutical Design

Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)
pp. 807-807(1)
Authors: Giovannetti, E.; Peters, G.J.

Targeting HER Receptors in Cancer
pp. 808-817(10)
Authors: Ocana, Alberto; Pandiella, Atanasio

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
pp. 818-832(15)
Authors: Galvani, Elena; Alfieri, Roberta; Giovannetti, Elisa; Cavazzoni, Andrea; La Monica, Silvia; Galetti, Maricla; Fumarola, Claudia; Bonelli, Mara; Mor, Marco; Tiseo, Marcello; J. Peters, Godefridus; Giorgio Petronini, Pier; Ardizzoni, Andrea

Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
pp. 833-840(8)
Authors: Voortman, J.; Harada, T.; Chang, R.P.; Killian, J.K.; Suuriniemi, M.; Smith, W.I.; Meltzer, P.S.; Lucchi, M.; Wang, Y.; Giaccone, G.

Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
pp. 841-863(23)
Authors: Lemos, Clara; Sack, Ulrike; Schmid, Felicitas; Juneja, Manisha; Stein, Ulrike

Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
pp. 864-882(19)
Authors: Santarpia, Libero; Bottai, Giulia

Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
pp. 883-894(12)
Authors: Cossa, Giacomo; Gatti, Laura; Cassinelli, Giuliana; Lanzi, Cinzia; Zaffaroni, Nadia; Perego, Paola

PI3K Pathway Inhibitors: Better Not Left Alone
pp. 895-906(12)
Authors: Markman, Ben; J. Tao, Jessica; Scaltriti, Maurizio

The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
pp. 907-917(11)
Authors: Wouters, An; Boeckx, Carolien; B. Vermorken, Jan; Van den Weyngaert, Danielle; Peeters, Marc; Lardon, Filip

Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
pp. 918-926(9)
Authors: Porcelli, L.; Quatrale, A.E.; Mantuano, P.; Silvestris, N.; Rolland, J.F.; Biancolillo, L.; Paradiso, A.; Azzariti, A.

Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells
pp. 927-939(13)
Authors: Giovannetti, E.; Labots, M.; Dekker, H.; Galvani, E.; Lind, J.S.W.; Sciarrillo, R.; Honeywell, R.; Smit, E.F.; Verheul, H.M.; Peters, G.J.

Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer
pp. 940-950(11)
Authors: Avan, Amir; Quint, Karl; Nicolini, Francesco; Funel, Niccola; E. Frampton, Adam; Maftouh, Mina; Pelliccioni, Serena; J. Schuurhuis, Gerrit; J. Peters, Godefridus; Giovannetti, Elisa

Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
pp. 951-957(7)
Authors: S. Narayan, Ravi; Alexandre Fedrigo, Carlos; J.A. Stalpers, Lukas; G. Baumert, Brigitta; Sminia, Peter

Irinotecan Resistance is Accompanied by Upregulation of EGFR and Src Signaling in Human Cancer Models
pp. 958-964(7)
Authors: Petitprez, Amelie; K. Larsen, Annette